Meropenem and Piperacillin Plasma Concentrations During CRRT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04203784

Acronym

ABC2

Enrollment

135

Registered

2019-12-18

Start date

2012-11-01

Completion date

2016-12-31

Last updated

2019-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic, Hemolysis, Infection, Renal Replacement Therapy, Sepsis

Brief summary

This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).

Interventions

OTHERPlasma concentration measurements

Plasma concentration measurements

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* patients treated in the study ICU and * simultaneous CRRT and antibiotic treatment with either meropenem or piperacillin-tazobactam.

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Plasma antibiotic concentrations at mid and end of dosing interval	1 week	We vill report the measured plasma antibiotic concentrations at the mid and end of the dosing interval.
Relationships between plasma antibiotic concentrations and CRRT dose.	1 week	We will report the correlation between measured plasma concentrations of either antibiotic and the intensity of the CRRT treatment.
Influence of residual diuresis on the measured plasma antibiotic concentrations.	1 week	We will report the correlation between measured plasma concentrations of either antibiotic and residual diuresis.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026